Understanding respiratory syncytial virus (rsv). Causes and care.

• Facebook
• X
• Line

Respiratory Syncytial Virus (RSV) is a widespread pathogen that primarily affects the respiratory tract and is most common during the winter months, typically between October and March. This virus is the leading cause of hospitalization in infants and infects most children by the time they are two years old. In adults, RSV usually causes only mild, cold-like symptoms.

RSV belongs to the Pneumoviridae family and is a negative-sense RNA virus. Its name is derived from the characteristic multi-nucleated cells, known as syncytia, which form when infected cells merge. The formation of these syncytia is a typical feature of an RSV infection.

While the virus is generally harmless in healthy adults and older children, it can lead to severe complications such as bronchiolitis or pneumonia in infants, young children, and immunocompromised individuals. Since 2024, new prevention options have become available, including monoclonal antibodies and vaccines.

Key Points

• RSV is the most common cause of hospitalization for infants and infects nearly all children by the age of two.
• The virus is most prevalent during the winter months and can cause a range of illnesses, from mild cold-like symptoms to severe respiratory disease.
• New preventive measures, such as monoclonal antibodies and vaccines, offer improved protection for high-risk groups.

Contents

1. Definition and Virology of Respiratory Syncytial Virus

• Taxonomy and Virus Structure
• Virus Strains: RSV-A and RSV-B
• Syncytia Formation and Replication Mechanism

2. Transmission, Epidemiology, and Risk Groups

• Infection Routes and Seasonality
• At-Risk Patients: Infants, Toddlers, and Premature Babies
• Prevalence in Different Age Groups

3. Symptoms, Disease Progression, and Complications

• Clinical Symptoms in Different Age Groups
• Upper Respiratory Tract Illnesses
• Lower Respiratory Tract Illnesses and RSV Bronchiolitis
• Severe Courses and Complications

4. Diagnosis, Therapy, and Prevention

• Diagnostic Methods: PCR, Antigen Tests, and Serology
• Symptomatic Therapy and Supportive Measures
• Specific and Antiviral Therapies
• Prevention, Vaccines, and Prophylaxis

Respiratory Syncytial Virus (RSV) is an RNA virus from the Pneumoviridae family that primarily causes respiratory infections in infants and young children. Its virological structure includes specific surface proteins and a characteristic replication mechanism involving the formation of syncytia.

RSV belongs to the Pneumoviridae family and is scientifically classified as an Orthopneumovirus. The complete taxonomic classification ranges from the phylum Negarnaviricota to the genus Orthopneumovirus.

RSV is a single-stranded, negative-sense RNA virus ((-)ssRNA virus) with an unsegmented genome. The viral genome contains 10 genes that encode for a total of 11 different viral proteins.

The virus structure consists of a double-layered lipid envelope with embedded glycoproteins. The most important surface proteins are:

• F-protein (Fusion protein)
• G-protein (Adhesion protein)
• SH-protein (Small Hydrophobic Protein)

The virion has a diameter of approximately 150-300 nanometers. In English-speaking regions, RSV is increasingly referred to as Human Orthopneumovirus, although this nomenclature has not yet become established in Germany.

RSV exists in two main virus strains: RSV-A (RSVA) and RSV-B (RSVB). The distinction is made based on the antigenic structure of the G-protein on the virus surface.

RSVA shows a dominant tendency in prevalence compared to RSVB. However, both strains circulate simultaneously in the population and can co-occur during an RSV season.

The virus strains differ in their:

• Antigenic structure
• Pathogenicity
• Immune response in the host

In addition to Human Respiratory Syncytial Virus (HRSV), there are species-specific variants such as Bovine Respiratory Syncytial Virus (BRSV), which affects cattle. These viruses are specialized for their respective host species.

The replication cycle begins with the attachment of the virus to the host cell’s surface receptors via the G-protein. The F-protein then enables fusion with the plasma membrane of the epithelial cells.

After fusion, the ribonucleocapsid is released into the cytoplasm. The viral mRNA is capped and polyadenylated in the cytoplasm before protein biosynthesis begins.

The characteristic formation of syncytia results from the fusion of infected epithelial cells. These namesake syncytia are multinucleated giant cells created by the virus’s fusion protein.

The replication process leads to:

• Necrosis of epithelial cells
• Inflammatory exudates
• Airway narrowing
• Impairment of lung function

New virions are released through the interaction of ribonucleocapsids with matrix proteins beneath the plasma membrane.

RSV spreads mainly through droplet infection and contaminated surfaces, with the typical RSV season lasting from October to March. Infants and premature babies are at the highest risk for severe respiratory diseases, and nearly all children will have had at least one RSV infection by the time they are two years old.

The primary transmission of RSV is through droplet infection from infected individuals. The mucous membranes of the upper respiratory tract and conjunctiva (the lining of the eyelids) are the main entry points for the virus.

Indirect transmission is possible via contaminated hands, objects, and surfaces. RSV can remain infectious for 20 minutes on hands, 45 minutes on paper towels, and several hours on plastic surfaces.

RSV Season and Seasonality:

• Main season: November/December to March/April
• Peak: Usually January and February
• Sporadic infections outside of the main season are possible

The COVID-19 pandemic shifted the usual seasonal pattern. During the 2020/21 winter season, the regular wave of RSV illness was absent in Germany. Following the easing of infection control measures, RSV circulated unusually early in 2021, from August to December.

Adolescents and adults often act as asymptomatic carriers. Inadequate hygiene measures can lead to rapid nosocomial (hospital-acquired) spread.

Infants and toddlers are particularly vulnerable to severe RSV-related respiratory infections. Within the first year of life, 50-70% of all children will have experienced an RSV infection.

Passive immunity from maternal antibodies only protects newborns for the first 4-6 weeks of life. Premature infants receive fewer maternal antibodies and can become severely ill even in their first few weeks.

High-risk groups among children:

• Premature infants
• Children with chronic lung diseases
• Children with severe heart conditions and congenital heart defects
• Immunodeficient children
• Children with neuromuscular diseases
• Children with syndromic conditions such as Trisomy 21

Severe, hospitalized cases show varying mortality rates: 0.2% in otherwise healthy children, 1.2% in premature infants, and up to 5.2% in children with a congenital heart defect.

Boys are more frequently affected by severe, hospitalized RSV-related respiratory illnesses than girls.

RSV infections affect all age groups. By the end of their second year of life, nearly all children have had at least one RSV infection.

Long-term immunity does not develop. Re-infections are common, especially in adults who have regular contact with young children.

Adult risk groups:

• Individuals with pre-existing cardiac or pulmonary conditions
• Immunodeficient and immunosuppressed individuals
• Recipients of organ or cell transplants
• Individuals with a malignant hematological disease

The seasonality and symptoms of RSV infections are similar to those of influenza. Its prevalence in the general population was long underestimated.

Current global estimates show 95 cases per 1,000 children annually within their first year of life. Of these, 16 cases result in hospitalization.

Nosocomial (hospital-acquired) RSV infections are particularly significant for premature infants and immunosuppressed individuals. RSV is considered the most important pathogen causing nosocomial respiratory infections in infants.

RSV infections present different symptoms depending on the age group, with infants generally becoming more severely ill than older children and adults. The illness can range from mild cold-like symptoms to severe complications of the lower respiratory tract.

In adults and older children, RSV infections are usually mild with cold-like symptoms. Typical signs include a runny nose, cough, sore throat, and a slight fever.

The illness typically lasts from three to twelve days. However, a cough can persist for more than four weeks.

Infants and young children frequently develop more severe symptoms. Their immature immune systems and smaller airways make them more susceptible to complicated disease courses.

In infants, symptoms include:

• Rapid, labored breathing
• Persistent cough
• Fever or low body temperature (hypothermia)
• Refusal to feed
• Irritability or apathy

Premature infants are particularly at risk. Their incompletely developed immune systems and immature lungs make it significantly more difficult to fight off the virus.

RSV infections typically begin in the upper respiratory tract. Rhinitis, with a stuffy or runny nose, is often the first symptom to appear.

Pharyngitis (sore throat) often develops alongside rhinitis. Those affected complain of a sore throat and difficulty swallowing.

The combination of rhinitis and pharyngitis leads to the characteristic cold-like symptoms. In many older children and adults, the infection remains confined to these areas.

Fever often accompanies the upper respiratory symptoms. It can be more pronounced in infants than in older patients.

In infants, the infection frequently spreads to the lower respiratory tract. Tracheobronchitis develops as the virus spreads to the trachea and bronchi.

RSV bronchiolitis is the most severe form of the illness. The small airways (bronchioles) become inflamed and swell, leading to respiratory distress.

Characteristic signs of RSV bronchiolitis:

• Wheezing
• Retractions of the chest wall
• Cyanosis (bluish discoloration of the skin)
• Tachypnea (rapid breathing)

Bronchitis can occur as a milder form of lower respiratory tract involvement. It is characterized by a productive cough and bronchial obstruction.

Distinguishing between bronchitis and bronchiolitis is important for treatment planning.

Approximately 1-3% of infected infants require hospitalization. Severe cases occur most often in high-risk groups.

Pneumonia can develop from severe RSV infections. It can be unilateral (affecting one lung) or bilateral (affecting both lungs) and requires intensive medical care.

Life-threatening complications include:

• Respiratory failure
• Apnea episodes (periods of stopped breathing)
• Dehydration due to refusal to feed
• Secondary bacterial infections

Cases requiring mechanical ventilation occur primarily in premature infants and children with underlying health conditions. Mechanical ventilation becomes necessary in cases of severe hypoxemia (low blood oxygen levels).

Long-term consequences can include recurrent respiratory infections and an increased risk of developing asthma. However, most children recover completely without any permanent damage.

The diagnosis of an RSV infection is primarily made using molecular biology methods and antigen tests. Treatment focuses on symptomatic measures, while specific antiviral therapies are used only in special cases.

PCR (Polymerase Chain Reaction) is considered the gold standard for detecting RSV. It identifies viral RNA with high sensitivity and specificity.

Multiplex PCR systems can simultaneously differentiate RSV from other respiratory pathogens like SARS-CoV-2. This is particularly important as the symptoms can be similar.

Antigen tests offer a faster alternative to PCR. EIA (Enzyme Immunoassay) and IFT (Immunofluorescence Technique) can directly detect RSV antigens in respiratory secretions.

Point-of-care tests provide results within 15-30 minutes. However, their sensitivity is lower than PCR, especially in older children and adults.

Serology plays a subordinate role in acute diagnostics. It can be helpful for immunocompromised patients when other methods fail.

Symptomatic therapy is the cornerstone of RSV treatment. Adequate fluid intake and rest are fundamental measures for mild cases.

In severe cases, ventilation may be necessary. CPAP (Continuous Positive Airway Pressure) supports breathing in infants with bronchiolitis.

Bronchodilators such as Salbutamol generally show no significant benefit for RSV-induced bronchiolitis. Studies do not confirm a clear improvement in symptoms.

Glucocorticoids are not routinely recommended. They may be considered for certain high-risk groups, but their effectiveness is disputed.

Montelukast, a leukotriene receptor antagonist, has not shown a convincing effect in studies on acute RSV bronchiolitis. Therefore, its use is limited to exceptional cases.

Ribavirin is the only available antiviral medication for RSV. However, its effectiveness is controversial, and its use is restricted to specific patient groups.

Patients who have received stem cell transplants and those with malignant hematological diseases are most likely to benefit from Ribavirin therapy. The treatment is administered via inhalation or intravenously.

The side effects of Ribavirin can be significant. These include anemia, bronchospasm, and teratogenic effects in pregnant women.

New antiviral substances are currently under development. However, no other specific therapies for RSV have been approved to date.

For a long time, Palivizumab was the only available monoclonal antibody for prophylaxis in high-risk infants. It is administered monthly during the RSV season.

Nirsevimab represents a significant advancement. This long-acting monoclonal antibody requires only a single injection per RSV season.

The vaccines Arexvy and Abrysvo are approved for older adults and pregnant women, respectively. By means of maternal immunization, Abrysvo indirectly protects newborns.

Hygiene measures remain central to prevention. Regular handwashing, avoiding crowds, and maintaining distance from sick individuals significantly reduce the risk of infection.